Search details
1.
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
N Engl J Med
; 380(7): 617-628, 2019 02 14.
Article
in English
| MEDLINE | ID: mdl-30516102
2.
Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer.
Cancer
; 126(13): 3132-3139, 2020 07 01.
Article
in English
| MEDLINE | ID: mdl-32286687
3.
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
N Engl J Med
; 377(2): 122-131, 2017 Jul 13.
Article
in English
| MEDLINE | ID: mdl-28581356
4.
Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy.
Breast Cancer Res
; 21(1): 142, 2019 12 11.
Article
in English
| MEDLINE | ID: mdl-31829264
5.
PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial.
Breast Cancer Res
; 21(1): 39, 2019 03 11.
Article
in English
| MEDLINE | ID: mdl-30867034
6.
Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto.
Breast Cancer Res
; 21(1): 60, 2019 05 10.
Article
in English
| MEDLINE | ID: mdl-31077239
7.
Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial.
Int J Cancer
; 145(3): 857-868, 2019 08 01.
Article
in English
| MEDLINE | ID: mdl-30694523
8.
Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial.
Breast Cancer Res Treat
; 176(3): 557-568, 2019 Aug.
Article
in English
| MEDLINE | ID: mdl-31065870
9.
Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized Trials.
Ann Surg Oncol
; 26(12): 3892-3901, 2019 Nov.
Article
in English
| MEDLINE | ID: mdl-31350646
10.
A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA).
Anticancer Drugs
; 30(4): 394-401, 2019 04.
Article
in English
| MEDLINE | ID: mdl-30875348
11.
Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial.
Lancet Oncol
; 19(7): 987-998, 2018 07.
Article
in English
| MEDLINE | ID: mdl-29880292
12.
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Lancet Oncol
; 19(4): 497-509, 2018 04.
Article
in English
| MEDLINE | ID: mdl-29501363
13.
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Lancet Oncol
; 19(1): 40-50, 2018 01.
Article
in English
| MEDLINE | ID: mdl-29233559
14.
Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab.
Pharmacogenet Genomics
; 28(6): 147-152, 2018 06.
Article
in English
| MEDLINE | ID: mdl-29768301
15.
Molecular alterations in triple-negative breast cancer-the road to new treatment strategies.
Lancet
; 389(10087): 2430-2442, 2017 Jun 17.
Article
in English
| MEDLINE | ID: mdl-27939063
16.
Current approach of the axilla in patients with early-stage breast cancer.
Lancet
; 2017 Aug 14.
Article
in English
| MEDLINE | ID: mdl-28818521
17.
Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials.
Breast Cancer Res Treat
; 167(1): 59-71, 2018 01.
Article
in English
| MEDLINE | ID: mdl-28875243
18.
Clinical relevance and concordance of HER2 status in local and central testing-an analysis of 1581 HER2-positive breast carcinomas over 12 years.
Mod Pathol
; 31(4): 607-615, 2018 04.
Article
in English
| MEDLINE | ID: mdl-29271415
19.
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 18(12): 1688-1700, 2017 12.
Article
in English
| MEDLINE | ID: mdl-29146401
20.
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.
Lancet
; 387(10021): 866-73, 2016 Feb 27.
Article
in English
| MEDLINE | ID: mdl-26686313